Compare ACOG & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACOG | ORMP |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.6M | 170.3M |
| IPO Year | 2024 | 2010 |
| Metric | ACOG | ORMP |
|---|---|---|
| Price | $8.86 | $4.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | 162.7K | ★ 218.9K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | 41.58 | ★ 412.50 |
| EPS | N/A | ★ 2.76 |
| Revenue | ★ $10,220,275.00 | $2,000,000.00 |
| Revenue This Year | $139.22 | N/A |
| Revenue Next Year | $134.48 | N/A |
| P/E Ratio | ★ N/A | $1.73 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $4.50 | $2.09 |
| 52 Week High | $10.14 | $5.47 |
| Indicator | ACOG | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 50.75 |
| Support Level | $5.28 | $3.91 |
| Resistance Level | $9.04 | $5.10 |
| Average True Range (ATR) | 0.55 | 0.24 |
| MACD | -0.09 | -0.04 |
| Stochastic Oscillator | 3.91 | 13.58 |
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.